Market Overview - The Hong Kong stock market experienced a decline today, with major indices opening lower and continuing to fall throughout the day, leading to a low-level oscillation in the afternoon [1] - The Hang Seng Index closed down by 1.2%, with a cumulative decline of 1.32% for the week [1] - The Hang Seng Tech Index fell by 2.48%, accumulating a weekly decline of 1.46% [1] - The total market turnover reached 271.563 billion HKD [1] Sector Performance - Consumer and technology stocks were among the hardest hit, with BYD Electronics (00285.HK) dropping over 6% and XPeng Motors (09868.HK) falling over 5% [1] - Other notable declines included NetEase (09999.HK), NIO (09866.HK), and Lenovo Group (00992.HK), each down over 4% [1] - The newly listed company, Hand Return Group (02621.HK), saw a significant drop of over 18% on its first trading day [1] Pharmaceutical Sector - In contrast, the pharmaceutical sector showed positive performance, with Fosun Pharma (02196.HK) rising by 9.89% and CSPC Pharmaceutical Group (01093.HK) increasing by 6.3% [1]

Group 1 - Kingsoft Software (03888) saw a nearly 5% drop in stock price, with Q1 revenue increasing by 9% year-on-year to 2.338 billion yuan, but net profit attributable to the parent company slightly decreased by 0.24% to 284 million yuan. Office software and services revenue grew by 6% year-on-year but fell by 13% quarter-on-quarter, while online gaming and other revenue increased by 14% year-on-year but decreased by 20% quarter-on-quarter [1] - Li Auto-W (02015) rose over 7%, reporting a 1.1% year-on-year revenue increase and a 9.4% rise in net profit for Q1. The company expects Q2 delivery volume to increase by 13.3%-17.9% year-on-year, with revenue projected to grow by 2.5%-6.7%. CEO Li Xiang expressed confidence in restoring monthly sales to 50,000 units and plans to launch the pure electric SUV i8 in July [1] - Hand Return Group (02621) debuted on the market but fell over 7% on its first day. The company is an internet-based life insurance intermediary with platforms like Xiaoyusan, Kachaba, and Niubao100, raising approximately 134 million HKD from its listing [1] - Yiming Anke-B (01541) surged over 13%, with its stock price doubling within the month. The company announced preliminary efficacy and safety data for its core product IMM2510 in treating non-small cell lung cancer (NSCLC) during I/II phase clinical trials [1] Group 2 - Meizhong Jiahe (02453) increased by over 7%, having developed a proprietary proton therapy language model successfully deployed in a Guangzhou hospital. The company plans to raise approximately 93.94 million HKD through a discounted share placement for equipment procurement, loan repayment, and working capital [2] - Gome Retail (06808) rose over 6%, with reports indicating that after a major shareholder change, the company is on track to transform its business, focusing on sales scale and absolute gross profit by FY2026. The company turned profitable in the second half of the last fiscal year, reporting a net profit of 199 million yuan, and plans to distribute 1.5 billion yuan in dividends for FY2025 [2] - Sany International (00631) saw a rise of over 4%, reporting a 14.6% year-on-year revenue increase to 5.876 billion yuan and a 23.2% rise in net profit to 635 million yuan for Q1. Growth was attributed to global expansion, digitalization, and low-carbon strategies [2] Group 3 - Dekang Agriculture (02419) surged over 8%, with analysts noting that April pig prices remained strong despite the seasonal downturn, and May's supply-demand dynamics are expected to support rising pig prices. The company is recognized for its leading breeding costs, projected to be below 13 yuan per kilogram, with an estimated 30% growth in pig output over the next three years [3] - Fubo Group (03738) increased by over 13%, completing an oversubscribed financing of over 500 million HKD for AI research and financial optimization. The company reported a total revenue increase of approximately 23% year-on-year, with mainland China revenue growing by about 21% and monthly recurring revenue (MRR) increasing by around 30% [3] - Gako Si-B (01167) rose over 8%, with a cumulative increase of over 25% this week. The company received domestic approval for its KRAS G12C inhibitor, used in specific non-small cell lung cancer treatments [3] - Fosun Pharma (02196) increased by over 6%, announcing that its self-developed new drug, Luwo Meitini tablets, has been approved for market release by the National Medical Products Administration [3] Group 4 - The smartphone supply chain stocks collectively fell, with companies like Hillstone Technology dropping over 5% and Sunny Optical, BYD Electronics, and GoerTek all declining over 3%. This decline was attributed to market concerns following the reinstatement of tariffs from the Trump administration [4] - Xiansheng Pharmaceutical (02096) rose over 8%, with five of its drugs selected for the 2025 ASCO annual meeting. The company's innovative drug BD's international expansion has garnered attention, including a deal with AbbVie worth over 1 billion USD [4] - Yika (09923) surged over 10%, following a 27% increase the previous day. The company recently obtained a payment license in Arizona, USA, with a projected nearly 5-fold increase in overseas transaction volume in 2024 [4] - Stone Pharmaceutical Group (01093) rose over 7%, with ongoing negotiations for three potential transactions involving products like EGFR-ADC, with total potential payments reaching approximately 5 billion USD, one of which is expected to be completed in June [4]

Group 1 - The core point of the article is that the stock of Hand Return Group experienced a significant decline on its first day of trading in Hong Kong, opening over 7% lower than its issue price [1] - The opening price was reported at 7.5 HKD, while the issue price was set at 8.08 HKD [1]

Group 1 - The core viewpoint of the article is that Hand Return Group, a personal insurance intermediary service provider, has officially launched its IPO, planning to issue approximately 24.36 million shares at a price range of HKD 5.84 to HKD 8.08, with a listing date set for May 30 on the Hong Kong Stock Exchange [2] - The global offering consists of about 90% international placement (approximately 21.92 million shares) and 10% for public offering in Hong Kong (approximately 2.44 million shares), with cornerstone investors Tianjin Haitai Group and Luch Capital subscribing for a total of approximately HKD 49.55 million [2] - Based on the median issue price of HKD 7.28, the company's market capitalization post-listing is estimated to be around HKD 1.648 billion (approximately RMB 1.517 billion), with a price-to-sales (PS) ratio of 1.09 and a price-to-earnings (PE) ratio of 6.27 [2] Group 2 - According to the prospectus, Hand Return Group's revenue for 2022, 2023, and 2024 is projected to be RMB 806 million, RMB 1.634 billion, and RMB 1.387 billion, respectively, with adjusted net profits of RMB 75 million, RMB 253 million, and RMB 242 million, indicating a rising adjusted net profit margin reaching 17.4% by 2024 [3] - The company utilizes a digital platform to provide personal insurance transaction and service solutions, operating three major platforms: Xiao Yusan (online direct sales), Kachabao (agent distribution), and Niubao 100 (partner distribution), with over 1,900 insurance products distributed by the end of 2024 [3] - In 2023, the scale of personal insurance premiums in China reached RMB 500 billion, accounting for 14.6% of the total personal insurance market premiums, although the performance of insurance technology and intermediary platforms in the capital market has been mixed [3]

Core Viewpoint - Shenzhen Shouhui Technology Group Co., Ltd. has successfully passed the main board listing hearing on the Hong Kong Stock Exchange after multiple attempts, marking a significant step in its 18-month IPO journey [1][4]. Group 1: IPO Details - The company plans to globally offer 24.3584 million shares, with 22 million shares for international offering and 2.436 million shares for public offering in Hong Kong, at a price range of HKD 5.84 to HKD 8.08, aiming to raise up to HKD 196.8 million [1][3]. - The listing is expected to commence trading on May 30 [1]. Group 2: Financial Performance - The company has experienced significant financial volatility, with revenues of RMB 806 million, RMB 1.634 billion, and RMB 1.387 billion for the years 2022, 2023, and 2024 respectively, showing a 102.7% increase in 2023 followed by a 15.1% decline in 2024 [7]. - Cumulative net losses over two years reached RMB 4.92 billion, with losses of RMB 3.56 billion in 2023 and RMB 1.36 billion in 2024 [7][8]. Group 3: Business Model and Revenue Structure - The company primarily relies on insurance transaction commissions, with over 99% of its revenue coming from this source, while technology service income accounts for less than 1% [8]. - The "Niubao 100" platform contributed 62.8% of total insurance transaction service revenue in 2024, highlighting the vulnerability of its business model [6][8]. Group 4: Market Position and Competition - In 2023, the company held a 7.3% market share in the long-term personal insurance market, making it the second-largest online insurance intermediary in China [5]. - The company faces competition from major players like Ant Group and Tencent, which are pressuring smaller platforms [11]. Group 5: Governance and Internal Challenges - The company has faced internal governance issues, including a notable incident in 2020 involving a power struggle between co-founders, which raised concerns about its management stability [10]. - The company has also faced regulatory penalties for compliance violations, further intensifying investor concerns regarding its internal controls [10]. Group 6: Future Outlook - The company aims to use approximately 60% of the IPO proceeds to optimize its sales network and research and development, while the remaining funds will be allocated for liquidity and acquisitions [9]. - The future performance of the company remains uncertain, as it must navigate industry challenges and internal volatility post-IPO [11].

Core Viewpoint - A total of 9 companies submitted applications to the Hong Kong Stock Exchange from May 19 to May 25, with 1 company passing the hearing, 5 companies undergoing initial public offerings (IPOs), and 3 companies listing [1]. Group 1: Companies Submitting Applications - Fuwai Group Limited, a pan-Asian life insurance company, reported a projected net profit of $10 million for 2024, recovering from previous losses [2]. - Shandong Kuailu Technology Development Co., Ltd. focuses on short-distance green travel solutions, with a market share of 2.2% in mainland China's short-distance green travel technology services [3]. - Jushuitan Group Co., Ltd. is the largest e-commerce SaaS ERP provider in China, holding a 20.7% market share [4]. - Sany Heavy Industry Co., Ltd. ranks first in China and third globally in core engineering machinery revenue from 2020 to 2024, with a projected overseas market revenue share of 62.3% by 2024 [4][5]. - Lezi Tiancheng Cultural Development Co., Ltd. is the second-largest multi-category IP toy company in China, with revenues projected to grow from approximately 463 million RMB in 2022 to 630 million RMB in 2024 [6]. - Furuitek (Zhejiang) Intelligent Technology Co., Ltd. ranks second among third-party suppliers of intelligent driving solutions in China, with a market share of 7.2% [7]. - Shenzhen Huaxida Technology Co., Ltd. is a leading AI Home solution provider, ranking third in China by revenue [7]. - Kewang Pharmaceutical Group is a clinical-stage biopharmaceutical company with significant products in clinical development [8]. - Allianz International Holdings Limited is a Hong Kong security service provider with projected revenues of 114 million HKD in 2023 [9]. Group 2: Companies Passing Hearings and IPOs - Haitian Flavoring and Food Co., Ltd. is a leading condiment company in China, holding a 4.8% market share in the condiment market, which is projected to reach 498.1 billion RMB in 2024 [10]. - The company reported revenues of 25.61 billion RMB in 2022, with profits of 6.198 billion RMB [10]. Group 3: Companies Undergoing IPOs - Hengrui Medicine Co., Ltd. had a public offering that was oversubscribed by approximately 455 times, with a final issue price of 44.05 HKD per share [11]. - MIRXES-B had a global offering of 46.62 million shares, with a public offering oversubscription of 25.51 times [12]. - Jihong Co., Ltd. plans to issue 67.91 million shares, with a price range of 7.48 to 10.68 HKD per share [13]. - Paige Biopharma-B plans to issue 19.28 million shares at a price of 15.60 HKD per share [14]. - Shouhui Group plans to issue 24.36 million shares at a price range of 6.48 to 8.08 HKD per share [15]. Group 4: Companies Listing - CATL officially listed on the Hong Kong Stock Exchange with an opening price of 263 HKD per share, closing at 306.20 HKD, a 16.43% increase on the first day [16]. - MIRXES-B opened at 29 HKD per share and closed at 30 HKD, a 28.76% increase on its first day [17]. - Hengrui Medicine opened at 57 HKD per share and closed at 55.15 HKD, a 25.20% increase on its first day [18].

Regulatory Dynamics - Seven departments, including the Ministry of Science and Technology and the People's Bank of China, jointly issued policies to support the development of a technology finance system, focusing on venture capital, monetary credit, capital markets, technology insurance, and bond markets with 15 policy measures proposed [1] - The Financial Regulatory Bureau announced modifications to certain regulations to align with the latest requirements of the Company Law, including changes to the management of supervisory boards and related party transactions [1] Industry Dynamics - Several banks and insurance institutions are planning to abolish or not establish supervisory boards, with the audit committee of the board taking over their functions [4] - Three consumer finance companies have raised their maximum loan limits to 300,000 yuan, following a notification from the Financial Regulatory Bureau aimed at boosting consumption [4] Corporate Developments - China Construction Bank's former vice president, Zhang Gengsheng, was arrested for bribery and illegal loan issuance, with the case currently under further investigation [2] - The Beijing Financial Dispute Mediation Committee, the first of its kind in the financial industry, was established to provide mediation services and resolve financial disputes [3] - JD Group has taken over a consumer finance company, now named Tianjin JD Consumer Finance Co., Ltd., marking a significant shift in ownership [6] - Huaxia Bank's board chairman's qualifications were approved, and Ping An Life welcomed a new female general manager, signaling leadership changes in major financial institutions [7][8] Financial Performance - Ant Group reported a net profit of 38.3 billion yuan for 2024, a 61% increase year-on-year [11] - Xiaoying Technology's first-quarter net profit reached 458 million yuan, up 26.16% year-on-year, while its revenue grew by 60.39% [12] - Jia'nan Technology reported a first-quarter net loss of 86.43 million USD, a 119% increase in losses compared to the previous year [13] Overseas Dynamics - The SEC chairman announced plans to enhance cost-benefit analysis and develop a reasonable regulatory framework for the cryptocurrency market, emphasizing the need for transparency and accountability in digital asset regulation [10]

下周资本市场大事提醒：中国5月PMI数据将公布 英伟达将披露财报 6、MSCI中国指数新纳入芯原股份、百利天恒、惠泰医疗、光线传媒、海思科等6只股票；剔除海信家 电、一汽解放、上海医药、金诚信等17只股票。此次调整将于5月30日收盘后生效。 7、5月27日，国家统计局将公布工业经济效益月度报告。此前数据显示，4月份，规模以上工业增加值 同比实际增长6.1%。 8、下周四（5月29日），美联储将公布5月货币政策会议纪要。同日，美国第一季度实际GDP年化季率 修正值也将公布。5月30日美国将公布4月核心PCE物价指数。 9、周三（5月28日），英伟达将于美股盘后公布2026财年Q1财报。此外，赛富时、惠普、戴尔等AI产 业链重要参与者也将于下周发布财报。中概股投资者也将迎来拼多多、小米的财报，同时禾赛、亿航智 能、金山云等科技题材概念股也将披露最新业绩。 10、下周二至周四比特币2025大会将在拉斯维加斯举行。美国副总统万斯，以及Strategy、Robinhood的 首席执行官都会发表主题演讲。 11、受阵亡将士纪念日假期影响，美股5月26日（下周一）休市一日，同日，英国股市因春季银行假日 休市一日。CME旗下 ...

Macroeconomic and Policy Aspects - European Central Bank (ECB) President Lagarde indicated that the ECB will announce its latest interest rate decision on June 5, following seven rate cuts in the past year, with expectations for continued easing to boost economic growth [1] - U.S. Federal Reserve Chairman Powell maintained a stance of not rushing to cut rates during a commencement speech at Princeton University [2] - Bank of Japan Governor Ueda noted increased uncertainty from trade policies and indicated that future rate hikes will depend significantly on the impact of tariffs on the economy [1][2] Economic Data Releases - U.S. April durable goods orders are expected to drop sharply from 9.2% to -8.2%, while core capital goods orders are projected to rise slightly from 0.1% to 0.2% [2] - U.S. April PCE price index is anticipated to slow down by 0.1 percentage points to 2.2% year-on-year, with a month-on-month increase of 0.1% [3] Industry Events - OPEC+ announced plans to gradually increase production to 2.2 million barrels per day by 2026, with a significant increase of 411,000 barrels per day planned for July [4] - Huawei held a launch event for its new product, the Respect S800 [5] Company-Specific Events - Meituan is expected to report Q1 2026 revenue of 86.519 billion yuan, a year-on-year increase of 18.07%, with a focus on its delivery and local services [6] - Pinduoduo is projected to achieve Q1 2025 revenue of 103.368 billion yuan, a year-on-year increase of 19.07%, while expected earnings per share will decline by 9.77% [6] - Xiaomi is forecasted to report Q1 revenue of 106.92 billion yuan, a year-on-year growth of 41.6%, driven by recovery in the smartphone market and government subsidies [7]

Group 1 - Shouhui Group has officially launched its IPO, offering approximately 24.36 million shares at a price range of HKD 6.48 to HKD 8.08 per share, with a listing date expected on May 30 [1] - The funds raised from the IPO will be used for optimizing the sales network, R&D investment, and acquisitions, which will enhance the company's market competitiveness and business scale [1] Group 2 - Heng Rui Pharmaceutical's shares surged by 32.24% in the dark market, closing at HKD 58.25 after an initial offering price of HKD 44.05, indicating strong market confidence in its future [2] - The company reported a revenue of 27.985 billion yuan for 2024, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% from the previous year [2] Group 3 - Wei Hong Group Holdings expects a net loss of approximately 48.5 million Macanese Patacas for the fiscal year 2024, compared to a net loss of about 27.8 million Macanese Patacas in 2023, attributed to a decline in revenue [3] - The group's revenue for the reporting year is expected to be around 9.7 million Macanese Patacas, down from approximately 105.8 million Macanese Patacas in the previous year [3] Group 4 - Longqi Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its capital strength and international brand image, supporting its global business development [4] - The issuance will be subject to approval from the shareholders' meeting and relevant government and regulatory bodies [4] Group 5 - The Hang Seng Index closed at 23,544.31, down 1.19%, while the Hang Seng Tech Index fell by 1.70% to 5,251.75 [5] - The Yuqi Index also decreased by 1.19%, closing at 8,557.64 [5]